Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum

BERKELEY, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU.OB), announced today that Peter M. Strumph, Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) Investor Forum on Thursday, October 11, 2007 at 12:30 p.m. Pacific Time at The Palace Hotel in San Francisco, California. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including data from Nile's recently completed Phase Ia study for its lead compound, CD-NP.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at

About Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.

CD-NP, a novel chimeric natriuretic peptide currently in Phase I clinical studies for the treatment of heart failure, is a selective NPRB agonist which, in vivo, has been shown to have potent renal enhancement and cardiac unloading properties but with minimal hypotensive effects compared with competitive products. CD-NP is a rationally-designed synthetic peptide designed to incorporate favorable properties of naturally occurring natriuretic peptides. Data from Nile's recently completed Phase Ia study in healthy volunteers confirmed several pre-clinical findings, including that CD-NP activated its target receptor in humans, preserved renal function and caused increases in natriuresis and diuresis at doses associated with a minimal effect on mean arterial pressure. Nile believes that CD-NP could provide a valuable new treatment option for heart failure patients.

2NTX-99 is a novel small molecule that has been shown in vivo and in vitro to inhibit the synthesis and action of thromboxane (TXA2), enhance the production of endothelial prostacyclin (PGI2) and supply a pharmacological amount of nitric oxide (NO) to the vasculature. Nile believes that the unique activity profile of 2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

More information on Nile can be found at


Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.


Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Form 8-K filed with the Securities and Exchange Commission on September 21, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... commercializing novel treatments in oncology, endocrinology and women,s health, ... the Company,s former Senior Vice President, Chief Financial Officer, ... City office.  David A. ... the Company commented, "After a comprehensive review, the Company,s ...
(Date:10/12/2015)... , October 12, 2015 ... Dario™ Diabetes Management Solution, today announced its Medical Director, ... case study at MobiHealth,s 5th EAI International Conference ... "Transforming healthcare through innovations in mobile and wireless technologies," ... England from October 14 - 16, 2015. ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
Breaking Biology Technology:
(Date:10/8/2015)... , October 8, 2015 ... or the "Company"), a biometric authentication company focused ... of the Wocket® smart wallet announces that revenues ... were approximately $410,000 compared with $113,00 for the ... the 9 months ended September 30, 2015 were ...
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
(Date:10/6/2015)... Oct. 6, 2015  Maverix Biomics, Inc., a ... to its software portfolio with the debut of ... differential expression in eukaryotes. The software is integrated ... cloud-based genomic analysis solution that leverages proven open-source ... next-generation sequencing efforts. Garry Nolan,s ...
Breaking Biology News(10 mins):